Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL).

Full DD Report for RIGL

You must become a subscriber to view this report.


Recent News from (NASDAQ: RIGL)

After Hours Gainers / Losers (09/10/2018)
Top Gainers: ARTX +5.3% . NTNX +4.1% . SU +3.8% . TRXC +2.3% . RIGL +2.1% . More news on: Arotech Corporation, Nutanix, Suncor Energy Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 10 2018 17:36
Premarket Gainers as of 9:05 am (9/4/2018)
MNKD   +47%  on collaborating with United Therapeutics for pulmonary hypertension products. More news on: MannKind Corporation, TravelCenters of America LLC, Recro Pharma Inc, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 04 2018 09:24
New Research Coverage Highlights Argos Therapeutics, Triumph Group, Rigel Pharmaceuticals, Egalet, Hertz Global, and ACADIA Pharmaceuticals - Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Aug. 31, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Argos Therapeutics, Inc. (OTC:ARGS), Triumph Group, Inc. (NYSE:TGI), Rige...
Source: GlobeNewswire
Date: August, 31 2018 08:25

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-112.792.742.802.71641,168
2018-12-102.702.722.762.66984,369
2018-12-072.832.742.8352.701,314,829
2018-12-062.822.8152.85422.751,033,156
2018-12-053.062.873.162.874,210,457

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1162,006139,28844.5164Short
2018-12-10104,779260,63140.2020Short
2018-12-07164,388477,63334.4172Cover
2018-12-06101,269207,68048.7620Short
2018-12-04905,9261,125,50980.4903Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RIGL.


About Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL)

Logo for Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL)

Not available

 

Contact Information

 

 

Current Management

  • James Gower / CEO
  • James Welch / CFO, Secretary

Current Share Structure

  • Market Cap: $664,136,006 - 05/18/2018
  • Issue and Outstanding: 163,580,297 - 04/26/2018

 


Recent Filings from (NASDAQ: RIGL)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 08 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: August, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 31 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 18 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 23 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: April, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 20 2018

 

 


Daily Technical Chart for (NASDAQ: RIGL)

Daily Technical Chart for (NASDAQ: RIGL)


Stay tuned for daily updates and more on (NASDAQ: RIGL)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: RIGL)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RIGL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RIGL and does not buy, sell, or trade any shares of RIGL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/